Ilyang Pharmaceutical Co.,Ltd Cash Flow Conversion Efficiency

Latest as of June 2026: -0.026x

Ilyang Pharmaceutical Co.,Ltd cash flow conversion efficiency. Based on the latest financial reports, Ilyang Pharmaceutical Co.,Ltd (007575) has a cash flow conversion efficiency ratio of -0.026x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-6.76 Billion ≈ $-4.58 Million USD) by net assets (₩256.94 Billion ≈ $174.12 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Ilyang Pharmaceutical Co.,Ltd (2014–2025)

Cash flow conversion efficiency of Ilyang Pharmaceutical Co.,Ltd from 2014 to 2025. This chart illustrates how Ilyang Pharmaceutical Co.,Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Ilyang Pharmaceutical Co.,Ltd stock price for real-time trading data and today's change.

Ilyang Pharmaceutical Co.,Ltd Cash Flow Conversion Ratio Explained

Ilyang Pharmaceutical Co.,Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Ilyang Pharmaceutical Co.,Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ilyang Pharmaceutical Co.,Ltd ranked by their cash flow conversion efficiency. Also see 007575 company net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Nova Minerals Limited NYSE MKT:NVA	0.066x
Novogenia AG XETRA:7V0	N/A
Phenixfin Corporation NASDAQ:PFX	0.000x
Immutep Ltd ADR NASDAQ:IMMP	-0.284x
Byrna Technologies Inc NASDAQ:BYRN	0.073x
Zuari Agro Chemicals Limited NSE:ZUARI	0.202x
Compagnie Industrielle et Financière d'Entreprises SA PA:INFE	0.143x
SRP Groupe SA PA:SRP	0.135x

Annual Cash Flow Conversion Efficiency for Ilyang Pharmaceutical Co.,Ltd (2014–2025)

The table below shows the annual cash flow conversion efficiency of Ilyang Pharmaceutical Co.,Ltd from 2014 to 2025. Review 007575 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩241.41 Billion ≈ $163.60 Million	₩12.04 Billion ≈ $8.16 Million	0.050x	+112.78%
2024-12-31	₩239.53 Billion ≈ $162.33 Million	₩5.61 Billion ≈ $3.81 Million	0.023x	-68.51%
2023-12-31	₩196.41 Billion ≈ $133.10 Million	₩14.62 Billion ≈ $9.91 Million	0.074x	-27.43%
2022-12-31	₩291.85 Billion ≈ $197.79 Million	₩29.94 Billion ≈ $20.29 Million	0.103x	-58.41%
2021-12-31	₩271.76 Billion ≈ $184.17 Million	₩67.02 Billion ≈ $45.42 Million	0.247x	+5.08%
2020-12-31	₩244.92 Billion ≈ $165.98 Million	₩57.48 Billion ≈ $38.96 Million	0.235x	+44.44%
2019-12-31	₩222.74 Billion ≈ $150.95 Million	₩36.19 Billion ≈ $24.53 Million	0.162x	+54.17%
2018-12-31	₩209.88 Billion ≈ $142.23 Million	₩22.12 Billion ≈ $14.99 Million	0.105x	-25.94%
2017-12-31	₩210.98 Billion ≈ $142.98 Million	₩30.03 Billion ≈ $20.35 Million	0.142x	+14.64%
2016-12-31	₩217.35 Billion ≈ $147.30 Million	₩26.98 Billion ≈ $18.29 Million	0.124x	-34.96%
2015-12-31	₩211.00 Billion ≈ $142.99 Million	₩40.27 Billion ≈ $27.29 Million	0.191x	+87.97%
2014-12-31	₩183.46 Billion ≈ $124.33 Million	₩18.63 Billion ≈ $12.62 Million	0.102x	--

About Ilyang Pharmaceutical Co.,Ltd

KO:007575 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$83.96 Million

₩123.89 Billion KRW

Market Cap Rank

#19654 Global

#998 in Korea

Share Price

₩6820.00

Change (1 day)

-0.15%

52-Week Range

₩6820.00 - ₩8380.00

All Time High

₩141909.13